PCDHGB7 Increases Chemosensitivity to Carboplatin by Inhibiting HSPA9 via Inducing Apoptosis in Breast Cancer

Disease Markers
Siqi HouLei Zhang

Abstract

Breast cancer is one of the most serious cancers worldwide, and chemotherapy resistance frequently drives cancer progression. Triple-negative breast cancer (TNBC) has a high recurrence rate and poor prognosis given its resistance to chemotherapy. In our previous study, we found a remarkable abnormal methylation modification of the PCDHGB7 gene in breast cancer. However, the roles of PCDHGB7 in the progression and treatment of breast cancer are unclear. In this study, we examined the effects of PCDHGB7 on the sensitivity of TNBC cells to carboplatin and investigated the underlying mechanism. By knocking down and overexpressing PCDHGB7 in HS578T and BT549 cells, we confirmed that PCDHGB7 increases TNBC cell chemosensitivity to carboplatin. Mechanistically, we found that PCDHGB7 negatively regulates the expression of HSPA9, uplifting its inhibition on P53 translocation and caspase-3 activation. Thus, we demonstrated that PCDHGB7 increases chemosensitivity of TNBC cells to carboplatin by inhibiting HSPA9 via inducing apoptosis. PCDHGB7 and HSPA9 represent potential therapeutic targets for chemosensitivity in breast cancer.

References

Jul 1, 1989·Molecular and Cellular Biology·E A CraigC M Nicolet
Jun 28, 2002·Cancer Cell·Douglas R Green, Gerard I Evan
Sep 17, 2002·Current Opinion in Cell Biology·Marcus Frank, Rolf Kemler
Oct 10, 2002·Histology and Histopathology·R WadhwaS C Kaul
Dec 10, 2002·Experimental Gerontology·Sunil C KaulRenu Wadhwa
Oct 19, 2004·Nature Structural & Molecular Biology·Patrick D'SilvaElizabeth A Craig
Aug 16, 2005·Current Opinion in Cell Biology·Dirk JunghansRolf Kemler
Sep 29, 2005·Springer Seminars in Immunopathology·David PilzerZvi Fishelson
Jan 21, 2006·International Journal of Cancer. Journal International Du Cancer·Renu WadhwaSunil C Kaul
Jun 16, 2006·Carcinogenesis·Huidong ShiCharles W Caldwell
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Oct 16, 2007·Current Opinion in Cell Biology·Hirofumi Morishita, Takeshi Yagi
Dec 7, 2007·Annals of the New York Academy of Sciences·Custer C DeocarisRenu Wadhwa
May 16, 2009·Protein and Peptide Letters·Custer C DeocarisRenu Wadhwa
Jul 29, 2010·Cancer Control : Journal of the Moffitt Cancer Center·Roohi Ismail-Khan, Marilyn M Bui
Nov 10, 2010·Breast Cancer Research : BCR·Reinaldo D Chacón, María V Costanzo
Nov 12, 2010·The New England Journal of Medicine·William D FoulkesJorge S Reis-Filho
Jun 3, 2011·The Journal of Clinical Investigation·Brian D LehmannJennifer A Pietenpol
Sep 21, 2015·Oncotarget·Giuseppe PalmaMassimiliano D'Aiuto
Nov 27, 2015·Expert Opinion on Therapeutic Targets·Fouzia GuestiniHironobu Sasano
Jan 9, 2016·CA: a Cancer Journal for Clinicians·Rebecca L SiegelAhmedin Jemal
Jul 28, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Ming ShanGuoqiang Zhang
Jul 3, 2017·The Breast : Official Journal of the European Society of Mastology·Lironne Wein, Sherene Loi
Sep 25, 2017·Oncotarget·Hua-Chuan Zheng
May 16, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Min XuJiansong Ji
Aug 30, 2018·Anti-cancer Agents in Medicinal Chemistry·Zdzisław KrawczykDorota Scieglinska
Apr 13, 2019·Journal of Translational Medicine·Wijden MahfoudhAbdelfateh Zakhama

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR
protein assay
transfection
nuclear translocation

Software Mentioned

Prism

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis